Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront for the Non-opioid Neuropathic Pain Treatment, NRD.E1, for Greater China and Singapore  https://t.co/TkzfZYdNCZ  https://t.co/ZNMBATQN84